Is Chamomile Tea Safe in Pregnancy?
Perinatal Psychopharmacology · Sleep in Pregnancy
Is Chamomile Tea Safe in Pregnancy? Why the Gentlest Sleep Remedy Carries an NSAID-Like Risk
It is the most culturally "harmless" bedtime ritual in obstetrics — and it has a real pharmacologic mechanism most clinicians have never connected to the ductus arteriosus. Here is what to tell patients, and why dose and trimester decide the answer.
"Can I still drink chamomile tea?" may be the single most common herbal question in a prenatal clinic. It feels like an easy yes — chamomile is the most culturally embedded sleep remedy on earth, sold beside the diapers, served to children. But the honest clinical answer is more interesting than either "sure" or "avoid it," and it turns on a mechanism that most clinicians never think to apply to a cup of tea.
The mechanism nobody mentions
Chamomile's proposed sedative action comes from apigenin, a flavonoid that binds GABA-A receptors — though at concentrations far below those any pharmacologic GABAergic agent achieves, which is part of why the efficacy data are so thin. The clinically important molecule is the same one: apigenin is a polyphenol, and polyphenols inhibit prostaglandin synthesis.
Prostaglandin synthesis is exactly what keeps the fetal ductus arteriosus patent in utero. NSAIDs like indomethacin block the COX enzyme directly; chamomile's polyphenols get there differently — apigenin down-regulates COX-2 expression (largely via NF-κB), lowering prostaglandin output rather than inhibiting the enzyme's active site. The route differs, but the downstream effect converges: less prostaglandin, and the same theoretical risk of premature ductal constriction. This is why the AAFP's safety entry for chamomile reads, almost startlingly: "ductus arteriosus closure, increased preterm birth, low birth weight."
What the human data actually show
Two lines of evidence convert the mechanism from theoretical to clinically relevant.
| Study | Population | Key finding | Clinical signal |
|---|---|---|---|
| Zielinsky 2010 J Perinatol |
Maternal diet, 3rd trimester | Polyphenol intake >1,089 mg/day → significantly higher ductal flow velocities & altered right-to-left ventricular dimension ratios | Echocardiographic signature of ductal constriction; dose-dependent, T3-concentrated. A 2018 follow-up (Vian/Zielinsky) showed polyphenol restriction reversed the constriction and raised PGE2 |
| Cuzzolin 2010 Pharmacoepidemiol Drug Saf |
37 regular chamomile users (of 392 pregnant women) | Threatening miscarriage 21.6% and preterm labor 21.6% — higher than non-users; 2 neonatal malformations | Tiny sample (n=37), not statistically significant for most comparisons — hypothesis-generating only, but it coheres with the prostaglandin mechanism for habitual use |
And does it even work for sleep?
This is the part that resolves the risk-benefit calculation cleanly.
| Source | Verdict on chamomile for insomnia |
|---|---|
| 2024 SR / meta-analysis 10 RCTs, 772 participants |
Modest improvement in global sleep quality (PSQI WMD −1.88, 95% CI −3.46 to −0.31) and fewer awakenings — subjective scales, mostly non-pregnant adults |
| VA/DoD 2019 | No benefit over placebo for any critical insomnia outcome — daytime function, severity, efficiency, latency, total sleep time, awakenings, or quality |
| AAFP 2023 | "Lack of evidence of effectiveness" |
So the picture isn't "nothing" — it's a modest, inconsistent effect on subjective sleep-quality scores, none of it in pregnancy, and no benefit on the outcomes that actually define an insomnia disorder. Set that thin, non-pregnant benefit against a plausible third-trimester safety concern and the risk-benefit calculation still tips clearly one way.
The regulatory wrinkle
Under the Dietary Supplement Health and Education Act (1994), chamomile capsules and extracts require no pre-market proof of safety, efficacy, or content accuracy. The same quality-control void that produced melatonin products ranging from −83% to +478% of labeled content governs the chamomile aisle. A patient swallowing a "chamomile sleep" extract is taking an unknown polyphenol dose — a very different exposure from steeping a single tea bag.
The clinical bottom line: dose and trimester decide it
| Exposure | Position | Why |
|---|---|---|
| Occasional cup of tea a bag now and then |
Reasonable | Far less apigenin & total polyphenol than an extract; unlikely to cause harm |
| Concentrated / habitual use capsules, tinctures, blends, multiple strong cups daily |
Avoid | Polyphenol load high enough to engage the prostaglandin pathway — most clearly in the 3rd trimester |
| Any dose, as a sleep aid | No role | Zero efficacy case — even the "safe" version does nothing for sleep |
"An occasional cup of chamomile tea is unlikely to hurt anything. But the concentrated supplements — the capsules and sleep blends — I'd skip, especially in the third trimester. Chamomile works a little like a mild anti-inflammatory, and in high, regular doses that can affect a blood vessel in the baby's heart. And honestly, it hasn't been shown to actually help sleep. If sleep is the problem, let's use something that's both safer-studied and that works."
That last sentence is the bridge to the evidence-based path. The first-line answer for insomnia in pregnancy is not another herbal — it is CBT-I, which has real RCT evidence in pregnant populations (Felder's digital CBT-I trial in 208 pregnant women produced a between-group effect size of d = −1.03). When pharmacotherapy is warranted, Z-drugs are the best-studied prescription hypnotic in pregnancy — a 2025 cohort of roughly 4.3 million pregnancies found no increase in major malformations (Fung 2025). The chamomile conversation, done well, is the on-ramp to that discussion — not the destination.
Chamomile is a weak dietary prostaglandin suppressor whose only sleep benefit is a modest, subjective effect in non-pregnant adults: occasional tea is fine, but concentrated or habitual use — especially in the third trimester — is the wrong tool for a problem CBT-I solves better.
This post is one agent from the full chapter — valerian, passionflower, magnesium, L-theanine, CBD, St. John's wort and more, each with the mechanism, the pregnancy data, the guideline position, and clinic-ready counseling scripts and EMR templates.
Read the full chapter →
Antidepressants, mood stabilizers, antipsychotics, ADHD medications, and sleep agents across pregnancy and breastfeeding — every claim verified against primary sources, built for point-of-care lookup.
Explore the Series →
Every course, chapter, and clinical tool in one membership.
- Best value
- Maximum savings
- For committed learners
- Two months free vs. monthly
Discounts available for residents & students only. Email your program details and proof of student status to our support team.
Key References
- Powers EA, Tewell R, Bayard M. Over-the-counter medications in pregnancy: a review. Am Fam Physician. 2023;108(4):360–369.
- Zielinsky P, Piccoli AL Jr, Manica JL, et al. Maternal consumption of polyphenol-rich foods in late pregnancy and fetal ductus arteriosus flow dynamics. J Perinatol. 2010;30(1):17–21.
- Vian I, Zielinsky P, Zílio AM, et al. Increase of prostaglandin E2 and reversal of fetal ductal constriction after restriction of maternal polyphenol intake. Ultrasound Obstet Gynecol. 2018.
- Cuzzolin L, Francini-Pesenti F, Verlato G, et al. Use of herbal products among 392 Italian pregnant women: focus on pregnancy outcome. Pharmacoepidemiol Drug Saf. 2010;19(11):1151–1158. (37 regular chamomile users; small, hypothesis-generating, not statistically significant for most outcomes.)
- Systematic review & meta-analysis of chamomile on sleep quality (10 trials, 772 participants), 2024: PSQI WMD −1.88 (95% CI −3.46 to −0.31); modest, subjective, largely non-pregnant.
- Muñoz Balbontín Y, Stewart D, Shetty A, et al. Herbal medicinal product use during pregnancy and the postnatal period: a systematic review. Obstet Gynecol. 2019;133(5):920–932.
- Felder JN, Epel ES, Neuhaus J, et al. Efficacy of digital CBT for insomnia symptoms among pregnant women: a randomized clinical trial. JAMA Psychiatry. 2020;77(5):484–492.
- Fung et al. Z-drug use in pregnancy and risk of major malformations (cohort of ~4.3 million pregnancies). JAMA Psychiatry. 2025.
Responses